ForSight Robotics secures $125M to advance its robotic surgery platform, targeting cataract procedures and additional ...

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

Perfuse Therapeutics reveals promising Phase 2 trial results for PER-001, a potential treatment for glaucoma and diabetic ...

Intravitreal anti-VEGF agents effectively manage nAMD but require frequent injections, leading to poor adherence and ...

Recombinant tissue plasminogen activator (tPA)—a molecule approved for the treatment of acute stroke by the FDA in ...

As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and ...

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing ...

From laser vision correction to adjustable lens implants, the Center for Refractive Solutions at New York Eye and Ear ...

The ophthalmic drug development industry is undergoing significant transformation, marked by unprecedented advancements in ...

Funding will support continued product development, while the board is composed of “global leaders in posterior and anterior ...

Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...